Oxford Biomedica Plc INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021
September 22, 2021 07:00 ET
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford...
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director
July 15, 2021 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director Oxford, UK – 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy...
Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine
May 18, 2021 07:00 ET
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine
May 18, 2021 02:00 ET
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica plc Preliminary results for the year ended 31 December 2020
April 15, 2021 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica plcPreliminary results for the year ended 31 December 2020 Saving Lives Oxford, UK – 15 April 2021: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading cell and...
Oxford Biomedica signs a new three year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors
April 06, 2021 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica signs a new three year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors Oxford, UK – 6 April, 2021: Oxford...
Oxford Biomedica plc: Board Changes
February 03, 2021 07:00 ET
|
Oxford BioMedica plc
Board Changes Oxford, UK – 3 February, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces two changes to the...
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK
December 30, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK Oxford, UK – 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”...
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19
November 23, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19 Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the...
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director
November 23, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and...